FIFarhana Islam

Farhana Islam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farhana Islam has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Palliative Esophageal External Beam Radiation Therapy in Patients with Stent for Esophageal Cancer: A Retrospective Cohort Study

    by Emily Adams, Héloïse Lavoie-Gagnon, Farhana Islam, Michael Humer, Benjamin Mou, Theodora A. Koulis, David Kim, Siavash Atrchian

    Purpose Self-expandable metallic stents (SEMS) provide immediate but nondurable dysphagia relief in esophageal cancer, while external beam radiotherapy (EBRT) provides slower, more durable dysphagia relief. While the combination of SEMS with EBRT would seem to offer both rapid and durable dysphagia relief in the palliative setting, there remains controversy on its safety and efficacy. We investigated patient outcomes regarding EBRT after SEMS placement in patients with incurable esophageal cancer at a regional Canadian cancer program. Methods We conducted a single-centre retrospective chart review from January 2010 to July 2020 to compare stent-related complications and survival in patients with incurable esophageal cancer treated with SEMS alone or SEMS + EBRT at Kelowna General Hospital. Results 66 patients were included in the SEMS alone group and 26 in the SEMS + EBRT group. Patients treated with SEMS alone showed an average of 3.05 fewer stent-related complications compared to patients who received SEMS + EBRT. The SEMS alone group also had 9.05 greater odds of experiencing higher grade complications compared to the SEMS + EBRT group (p < 0.001). Patients in the SEMS + EBRT group survived significantly longer than those treated with SEMS alone, with a median overall survival of 163.5 days and 65 days, respectively. Conclusions SEMS monotherapy was associated with significantly fewer, yet higher grade stent-related complications compared to palliative EBRT after SEMS placement. SEMS + EBRT treatment was associated with significantly prolonged survival compared to SEMS alone. Prospective studies are needed to confirm these findings.


  • Polygenic Risk Score Analysis of Antidepressant Treatment Outcomes: A CAN-BIND-1 Study Report: Analyse des résultats du traitement antidépresseur à l’aide des scores de risque polygéniques : Rapport sur l’étude CAN-BIND-1

    by Leen Magarbeh, Samar S. M. Elsheikh, Farhana Islam, Victoria S. Marshe, Xiaoyu Men, Emytis Tavakoli, Martin Kronenbuerger, Stefan Kloiber, Benicio N. Frey, Roumen Milev, et al.

    Objective: The genetic architecture of antidepressant response is poorly understood. This study investigated whether polygenic risk scores (PRSs) for major psychiatric disorders and a personality trait (neuroticism) are associated with antidepressant treatment outcomes. Methods: We analysed 148 participants with major depressive disorder (MDD) from the Canadian Biomarker Integration Network for Depression-1 (CAN-BIND-1) cohort. Participants initially received escitalopram (ESC) monotherapy for 8 weeks. Nonresponders at week 8 received augmentation with aripiprazole (ARI), while responders continued ESC until week 16. Primary outcomes were remission status and symptom improvement measured at weeks 8 and 16. At week 16, post-hoc stratified analyses were performed by treatment arm (ESC-only vs. ESC + ARI). Eleven PRSs derived from genome-wide association studies of psychiatric disorders (e.g., MDD and post-traumatic stress syndrome (PTSD)) and neuroticism, were analysed for associations with these outcomes using logistic and linear regression models. Results: At week 8, a higher PRS for PTSD was nominally associated with a lower probability of remission (odds ratio (OR) = 0.08 [0.014–0.42], empirical p -value = 0.017) and reduced symptom improvement (beta (standard error) = −29.15 (9.76), empirical p -value = 0.019). Similarly, a higher PRS for MDD was nominally associated with decreased remission probability (OR = 0.38 [0.18–0.78], empirical p -value = 0.044). However, none of the results survived multiple testing corrections. At week 16, the stratified analysis for the ESC-only group revealed that a higher PRS for MDD was associated with increased remission probability (empirical p- value = 0.034) and greater symptom improvement (empirical p -value = 0.02). In contrast, higher PRSs for schizophrenia (empirical p -value = 0.013) and attention-deficit hyperactivity disorder (empirical p -value = 0.032) were associated with lower symptom improvement. No significant associations were observed in the ESC + ARI group. Conclusions: These findings suggest that PRSs may influence treatment outcomes, particularly in ESC monotherapy. Replication in larger studies is needed to validate these observations.


  • Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study

    by Samar S. M. Elsheikh, Victoria S. Marshe, Xiaoyu Men, Farhana Islam, Vanessa F. Gonçalves, Guillaume Paré, Daniel Felsky, James L. Kennedy, Benoit H. Mulsant, Charles F. Reynolds, et al.

    Late-life depression (LLD) is often accompanied by medical comorbidities such as psychiatric disorders and cardiovascular diseases, posing challenges to antidepressant treatment. Recent studies highlighted significant associations between treatment-resistant depression (TRD) and polygenic risk score (PRS) for attention deficit hyperactivity disorder (ADHD) in adults as well as a negative association between antidepressant symptom improvement with both schizophrenia and bipolar. Here, we sought to validate these findings with symptom remission in LLD. We analyzed the Incomplete Response in Late Life Depression: Getting to Remission (IRL-GRey) sample consisting of adults aged 60+ with major depression (N = 342) treated with venlafaxine for 12 weeks. We constructed PRSs for ADHD, depression, schizophrenia, bipolar disorder, neuroticism, general intelligence, antidepressant symptom remission and antidepressant percentage symptom improvement using summary statistics from the Psychiatric Genomics Consortium and the GWAS Catalog. Logistic regression was used to test the association of PRSs with venlafaxine symptom remission and percentage symptom improvement, co-varying for the genomic principal components, age, sex and depressive symptoms severity at baseline. We found a nominal (i.e., p value ≤ 0.05) association between symptom remission and both PRS for ADHD and (OR = 1.36 [1.07, 1.73], p = 0.011) and PRS for bipolar disorder (OR = 0.75 [0.58, 0.97], p = 0.031), as well as between percentage symptom improvement and PRS for general intelligence (beta = 6.81 (SE = 3.122), p = 0.03). However, the ADHD association was in the opposite direction as expected, and both associations did not survive multiple testing corrections. Altogether, these findings suggest that previous findings regarding ADHD PRS and antidepressant response (measured with various outcomes) do not replicate in older adults.


  • Open Access

    Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

    by Farhana Islam, Leen Magarbeh, Samar S. M. Elsheikh, Stefan Kloiber, Caroline W. Espinola, Venkat Bhat, Benicio N. Frey, Roumen Milev, Claudio N. Soares, Sagar V. Parikh, et al.

    Objectives: Treatment-emergent sexual dysfunction is frequently reported by individuals with major depressive disorder (MDD) on antidepressants, which negatively impacts treatment adherence and efficacy. We investigated the association of polymorphisms in pharmacokinetic genes encoding cytochrome-P450 drug-metabolizing enzymes, CYP2C19 and CYP2D6, and the transmembrane efflux pump, P-glycoprotein (i.e., ABCB1), on treatment-emergent changes in sexual function (SF) and sexual satisfaction (SS) in the Canadian Biomarker Integration Network in Depression 1 (CAN-BIND-1) sample. Methods: A total of 178 adults with MDD received treatment with escitalopram (ESC) from weeks 0–8 (Phase I). At week 8, nonresponders were augmented with aripiprazole (ARI) (i.e., ESC + ARI, n = 91), while responders continued ESC (i.e., ESC-Only, n = 80) from weeks 8–16 (Phase II). SF and SS were evaluated using the sex effects (SexFX) scale at weeks 0, 8, and 16. We assessed the primary outcomes, SF and SS change for weeks 0–8 and 8–16, using repeated measures mixed-effects models. Results: In ESC-Only, CYP2C19 intermediate metabolizer (IM) + poor metabolizers (PMs) showed treatment-related improvements in sexual arousal, a subdomain of SF, from weeks 8–16, relative to CYP2C19 normal metabolizers (NMs) who showed a decline, F(2,54) = 8.00, p < 0.001, q = 0.048. Specifically, CYP2C19 IM + PMs reported less difficulty with having and sustaining vaginal lubrication in females and erection in males, compared to NMs. Furthermore, ESC-Only females with higher concentrations of ESC metabolite, S-desmethylcitalopram (S-DCT), and S-DCT/ESC ratio in serum demonstrated more decline in SF ( r = −0.42, p = 0.004, q = 0.034) and SS ( r = −0.43, p = 0.003, q = 0.034), respectively, which was not observed in males. ESC-Only females also demonstrated a trend for a correlation between S-DCT and sexual arousal change in the same direction ( r = −0.39, p = 0.009, q = 0.052). Conclusions: CYP2C19 metabolizer phenotypes may be influencing changes in sexual arousal related to ESC monotherapy. Thus, preemptive genotyping of CYP2C19 may help to guide selection of treatment that circumvents selective serotonin reuptake inhibitor-related sexual dysfunction thereby improving outcomes for patients. Additionally, further research is warranted to clarify the role of S-DCT in the mechanisms underlying ESC-related changes in SF and SS. This CAN-BIND-1 study was registered on clinicaltrials.gov (Identifier: NCT01655706) on 27 July 2012.


  • Open Access

    ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 Study

    by Leen Magarbeh, Claudia Hassel, Maximilian Choi, Farhana Islam, Victoria S. Marshe, Clement C. Zai, Rayyan Zuberi, Roseann S. Gammal, Xiaoyu Men, Maike Scherf‐Clavel, et al.

    The P‐glycoprotein efflux pump, encoded by the ABCB1 gene, has been shown to alter concentrations of various antidepressants in the brain. In this study, we conducted a systematic review and meta‐analysis to investigate the association between six ABCB1 single‐nucleotide polymorphisms (SNPs; rs1045642, rs2032582, rs1128503, rs2032583, rs2235015, and rs2235040) and antidepressant treatment outcomes in individuals with major depressive disorder (MDD), including new data from the Canadian Biomarker and Integration Network for Depression (CAN‐BIND‐1) cohort. For the CAN‐BIND‐1 sample, we applied regression models to investigate the association between ABCB1 SNPs and antidepressant treatment response, remission, tolerability, and antidepressant serum levels. For the meta‐analysis, we systematically summarized pharmacogenetic evidence of the association between ABCB1 SNPs and antidepressant treatment outcomes. Studies were included in the meta‐analysis if they investigated at least one ABCB1 SNP in individuals with MDD treated with at least one antidepressant. We did not find a significant association between ABCB1 SNPs and antidepressant treatment outcomes in the CAN‐BIND‐1 sample. A total of 39 studies were included in the systematic review. In the meta‐analysis, we observed a significant association between rs1128503 and treatment response (T vs. C‐allele, odds ratio = 1.30, 95% confidence interval = 1.15–1.48, P value (adjusted) = 0.024, n = 2,526). We did not find associations among the six SNPs and treatment remission nor tolerability. Our findings provide limited evidence for an association between common ABCB1 SNPs and antidepressant outcomes, which do not support the implementation of ABCB1 genotyping to inform antidepressant treatment at this time. Future research, especially on rs1128503, is recommended.


  • Open Access

    Assessment of the Prevalence of Tuberculosis among the High Risk Populations of Bera, Pabna

    by M A Shah, Farhana Islam

    The study was conducted to evaluate the prevalence of tuberculosis among the populations of Bera, Pabna from January to December 2021. Samples (Sputum) were collected from 09 different unions of susceptible pulmonary TB patients of different ages and occupations by field health workers in Bera, Pabna using a pretest and questionnaire. A gross of 4353 samples (January-December 2021) was tested by fluorescent smear microscope and GeneXpert, in the middle of them, 2442 (56%) were male, and the rest of 1911 (44%) were female. We stained 2577 samples and 151 participants tested positive. By the GeneXpert method, we tested 1776 samples and 266 tested positive. We identify a total of 417 sputa positive, of these 253 (61%) were male and 164 (39%) were female. We found a total of 542 positive TB patients from January to December 2021, in the middle of them, Bacteriologically confirm 405 (75%), Clinically diagnosed 25 ( 5% ), Extrapulmonary 78 (14%), Retreatment 32 (6%) and Failure 2 (0%). The maximum positive TB patient's age was >65 years. In comparisons between 2020 and 2021, the number of positive TB patients in 2020 was 408, and in 2021 was 542. Microscopy and Xpert test together to make it possible for large amounts of presumptive tests and diagnosed easily to determine the prevalence of tuberculosis. The overall prevalence of pulmonary tuberculosis among the participants was 9.6%.

  • Open Access

    Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

    by Farhana Islam, Victoria S. Marshe, Leen Magarbeh, Benicio N. Frey, Roumen V. Milev, Claudio N. Soares, Sagar V. Parikh, Franca Placenza, Stephen C. Strother, Stefanie Hassel, et al.

    Cytochrome P450 drug-metabolizing enzymes may contribute to interindividual differences in antidepressant outcomes. We investigated the effects ofCYP2C19andCYP2D6gene variants on response, tolerability, and serum concentrations. Patients (N = 178) were treated with escitalopram (ESC) from weeks 0–8 (Phase I), and at week 8, either continued ESC if they were responders or were augmented with aripiprazole (ARI) if they were non-responders (CYP2C19intermediate and poor metabolizers (IM + PMs), with reduced or null enzyme function, trended towards significantly lower symptom improvement during Phase II compared to normal metabolizers (NMs), which was not observed in ESC + ARI. We further showed thatCYP2D6NMs and IM + PMs had a higher likelihood of reporting a treatment-related central nervous system side effect in ESC-Only and ESC + ARI, respectively. The differences in the findings between ESC-Only and ESC + ARI may be due to the altered pharmacokinetics of ESC by ARI coadministration in ESC + ARI. We provided evidence for this postulation when we showed that in ESC-Only,CYP2C19andCYP2D6IM + PMs demonstrated significantly higher ESC concentrations at Weeks 10 and 16 compared to NMs. In contrast, ESC + ARI showed an association withCYP2C19but not withCYP2D6metabolizer group. Instead, ESC + ARI showed an association betweenCYP2D6metabolizer group and ARI metabolite-to-drug ratio suggesting potential competition between ESC and ARI for CYP2D6. Our findings suggest that dosing based onCYP2C19andCYP2D6genotyping could improve safety and outcome in patients on ESC monotherapy.


  • Open Access

    Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis

    by Farhana Islam, Daniel Hain, David Lewis, Rebecca Law, Lisa C. Brown, Julie-Anne Tanner, Daniel J. Müller

    Although clozapine is the most effective pharmacotherapy for treatment-resistant schizophrenia, it is under-utilized, and initiation is often delayed. One reason is the occurrence of a potentially fatal adverse reaction, clozapine-induced agranulocytosis (CIA). Identifying genetic variations contributing to CIA would help predict patient risk of developing CIA and personalize treatment. Here, we (1) review existing pharmacogenomic studies of CIA, and (2) conduct meta-analyses to identify targets for clinical implementation. A systematic literature search identified studies that included individuals receiving clozapine who developed CIA and controls who did not. Results showed that individuals carrying the HLA-DRB1*04:02 allele had nearly sixfold (95% CI 2.20–15.80, pcorrected = 0.03) higher odds of CIA with a negative predictive value of 99.3%. Previously unreplicated alleles, TNFb5, HLA-B*59:01, TNFb4, and TNFd3 showed significant associations with CIA after multiple-testing corrections. Our findings suggest that a predictive HLA-DRB1*04:02-based pharmacogenomic test may be promising for clinical implementation but requires further investigation.


  • Open Access

    Potentiality on e-commerce in the rural community of Bangladesh

    by F Islam, Mmh Kazal, Mh Rahman

    Bangladesh is a least developed country where a large number of population in rural areas live under substantial poverty. Recently, a phenomenal growth has witnessed in accessing mobile phone and internet which showing a new way for trade and commerce (e-commerce). But it is a big challenge to establish and provide the facilities of e-commerce to the majority population live in rural areas. This study explores the potential role of e-commerce in promoting sustainable and equitable development in rural areas. We discuss the possibilities of using e-commerce technology in a way that will benefit the rural communities. The growth of mobile and internet users, the digital divide between rural and urban population, problems related with dispersing the service of e-commerce in rural areas and future prospects are presented. There are a number of challenges but however, recently introduced community e-centers has a good potential which can provide the services of e-commerce in rural areas. In addition, to support low-income rural population, there is a need for governmental funding for expansion and development of rural infrastructure. This study might be helpful for the policy makers to implement the appropriate development strategy for reducing poverty and betterment of living standard in rural areas.Progressive Agriculture 27 (2): 207-215, 2016